Point-of-care testing technology has exceptional capabilities for detecting biomarkers for a wide range of diseases thanks to its speed, ease of use, efficiency and cost-effectiveness. One such POCT strategy is the lateral flow immunoassay. It is a well-established testing platform and a powerful tool for rapid, low-cost detection as it requires no specialized equipment, and results can be observed directly with the naked eye.

To improve the sensitivity and specificity of LFA and enable the quantitative analysis of test results, researchers have developed fluorescence immunochromatographic assays that use fluorescent reporter molecules. Compared to conventional methods, fluorescent immunoassays offer greater sensitivity as they produce higher-intensity bands on both the test and control lines.

Quantum dots (QDs) are a highly promising class of fluorescent reporter molecule. These are minute semiconductor nanocrystals with diameters ranging from 2 to 10 nanometres. They possess unique electronic properties that lie between those of bulk semiconductors and discrete molecules, partly due to their high specific surface area. The most intuitive manifestation of this is the phenomenon of fluorescence, whereby the nanocrystals emit different colours depending on their size.

CD Bioparticles offers custom services to assist researchers in developing quantum dot lateral flow assays. The company's services range from custom nanoparticle conjugates to fully optimizing lateral flow assays. Due to their high sensitivity, excellent photostability, ease of functionalization, multiplexing capabilities, and potential for quantitative analysis, quantum dot lateral flow assays are widely used in medical diagnostics, environmental monitoring, food safety testing, and biomarker detection.

CD Bioparticles offers a comprehensive range of quantum dot lateral flow assay development services, including covalent conjugation of antibodies/proteins to quantum dots, conjugation of aptamers/oligonucleotides to quantum dots, optimization of antibody-based sandwich, direct and competitive lateral flow assays, optimization of aptamer/oligonucleotide-based lateral flow assays, quantitative detection and bulk production.

CD Bioparticles' dedicated technical support team has extensive experience in providing comprehensive services covering sample preparation, selection of key materials, experimental protocol design, and validation of detection methods. The company possesses specialist expertise in optimizing running buffers, conjugation methods and nanoparticles. The company can assist clients in transferring and optimizing existing proof-of-concept detection methods into rapid flow cytometry-based protocols.

The company also possesses large-scale production capabilities and can manufacture high-quality nanoparticles, such as gold colloids, upconversion nanoparticles and quantum dots, for use in rapid diagnostic testing. The company can supply uniform nanoparticles with varying sizes and surface properties for LFA development.

For more information on the Quantum Dot Lateral Flow Assay development services or to inquire about a custom project, please visit https://www.cd-bioparticles.com/services/quantum-dot-lateral-flow-assay-development.html.

About CD Bioparticles

CD Bioparticles is a leading manufacturer and supplier of various nanoparticles, microparticles, and coatings for R&D as well as commercialization across different application areas, including in vitro diagnostics, biochemistry, cellular analysis, cell separation, and immunoassay. The company also offers various custom services, including chemical surface-functionalization, fluorescent modification, antibody immobilization, as well as nucleic acid and oligo conjugation to meet client specifications.